Please login to the form below

Not currently logged in
Email:
Password:

bioMérieux launches chromID MRSA medium

bioMérieux has launched a new version of chromID MRSA chromogenic medium for the detection of MRSA

bioMérieux has launched a new version of chromID MRSA chromogenic medium for the detection of methicillin resistant Staphylococcus aureus (MRSA), providing a cost-effective solution for rapid routine screening. 

With a maximum read time of 24 hours, compared to 48 hours for the previous version, the new version chromID agar has the potential to increase throughput significantly.

Daniel White, product manager, bioMérieux, said: "Compared to traditional culture media, chromogenic media offer the laboratory an easier method of identifying bacteria through colour differentiation.

"The intensity and specificity of the colours produced make rapid, easy identification of bacterial colonies possible; this new chromID MRSA chromogenic medium will be a great advantage to our customers releasing time and space within the laboratory while at the same time allowing earlier reporting of negatives to facilitate faster clinical decisions."

A ready-to-use medium for the culture, isolation and identification of MRSA, it offers direct identification of MRSA strains within 18 hours, and sensitivity is increased by a further seven per cent when flocked swabs are used for transportation, providing a good synergy with the PREVI Isola automated plate streaker.

The characteristic colours of the colonies – pale blue-green at 18 hours incubation and blue­ green to dark blue at 24 hours incubation – make results easy to read, and the medium has been validated for use with PREVI Isola, VITEK2 and API platforms.

14th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...

Infographics